Oestrogen Hormone Receptors in Focal Nodular Hyperplasia

Overview

Journal HPB (Oxford)

Publisher Elsevier

Specialty Gastroenterology

Date 2015 Mar 3

PMID 25728618

Citations 6

Authors

Manju D Chandrasegaram

Ali Shah

John W Chen

Andrew Ruszkiewicz

David S Astill

Georgina England

Ravish S Raju

Eu Ling Neo

Paul M Dolan

Chuan Ping Tan

Mark Brooke-Smith

Tom Wilson

Robert T A Padbury

Christopher S Worthley

Affiliations

Soon will be listed here.

Abstract

Background: The role of hormones in focal nodular hyperplasia (FNH) has been investigated with conflicting results.

Objective: The aim of this study was to evaluate oestrogen and progesterone receptor immunohistochemical expression in FNH and surrounding normal liver (control material).

Methods: Biopsy materials from FNH and control tissue were investigated using an immunostainer. Receptor expression was graded as the proportion score (percentage of nuclear staining) and oestrogen receptor intensity score.

Results: Study material included tissue from 11 resected FNH lesions and two core biopsies in 13 patients (two male). Twelve samples showed oestrogen receptor expression. The percentage of nuclear oestrogen receptor staining was <33% in eight FNH biopsies, 34-66% in two FNH biopsies, and >67% in both core biopsies. The better staining in core biopsies relates to limitations of the staining technique imposed by the fibrous nature of larger resected FNH. Control samples from surrounding tissue were available for nine of the resected specimens and all showed oestrogen receptor expression. Progesterone receptor expression was negligible in FNH and control samples.

Conclusions: By contrast with previous studies, the majority of FNH and surrounding liver in this cohort demonstrated oestrogen receptor nuclear staining. The implications of this for continued oral contraceptive use in women of reproductive age with FNH remain uncertain given the lack of consistent reported growth response to oestrogen stimulation or withdrawal.

Citing Articles

Pedunculated Focal Nodular Hyperplasia: When in Doubt, Should We Cut It Out?.

Tsalikidis C, Mitsala A, Pappas-Gogos G, Romanidis K, Tsaroucha A, Pitiakoudis M J Clin Med. 2023; 12(18).

PMID: 37762973 PMC: 10532121. DOI: 10.3390/jcm12186034.

Laparoscopic resection for pedunculated focal nodular hyperplasia of the liver during pregnancy.

Akaguma A, Ishii T, Uchida Y, Chigusa Y, Ueda Y, Mandai M Oxf Med Case Reports. 2023; 2023(6):omad054.

PMID: 37377714 PMC: 10292637. DOI: 10.1093/omcr/omad054.

A case of hepatic focal nodular hyperplasia mimicking hepatocellular carcinoma identified on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography.

Bilgic S, Sayman H, Sager M, Sonmezoglu K World J Nucl Med. 2021; 20(2):192-194.

PMID: 34321974 PMC: 8285996. DOI: 10.4103/wjnm.WJNM_108_20.

Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth?.

Ashhab A, Abu-Sulb A, Yang J, Noureddin M, Sundaram V, Kuo A ACG Case Rep J. 2021; 8(1):e00531.

PMID: 33457441 PMC: 7808515. DOI: 10.14309/crj.0000000000000531.

Benign Liver Tumors.

Oldhafer K, Habbel V, Horling K, Makridis G, Wagner K Visc Med. 2020; 36(4):292-303.

PMID: 33005655 PMC: 7506257. DOI: 10.1159/000509145.

References

Mathieu D, Kobeiter H, Maison P, Rahmouni A, Cherqui D, Zafrani E . Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology. 2000; 118(3):560-4. DOI: 10.1016/s0016-5085(00)70262-9. View

Reddy K, Kligerman S, Levi J, Livingstone A, Molina E, Franceschi D . Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg. 2001; 67(2):173-8. View

Hardwigsen J, Pons J, Veit V, Garcia S, Le Treut Y . A life-threatening complication of focal nodular hyperplasia. J Hepatol. 2001; 35(2):310-2. DOI: 10.1016/s0168-8278(01)00096-4. View

Kubota T, Shimizu K, Sonoyama T, Ikeda E, Kurioka H, Ouchi T . Enlarged focal nodular hyperplasia of the liver under the influence of oral contraceptives. Hepatogastroenterology. 2002; 48(42):1736-9. View

Dhalluin V, Vilgrain V, Pelletier G, Rocher L, Belghiti J, Erlinger S . [Natural history of focal nodular hyperplasia. A retrospective study of 44 cases]. Gastroenterol Clin Biol. 2002; 25(11):1008-10. View

Scalori A, Tavani A, Gallus S, La Vecchia C, Colombo M . Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol. 2002; 186(2):195-7. DOI: 10.1067/mob.2002.120277. View

Luciani A, Kobeiter H, Maison P, Cherqui D, Zafrani E, Dhumeaux D . Focal nodular hyperplasia of the liver in men: is presentation the same in men and women?. Gut. 2002; 50(6):877-80. PMC: 1773241. DOI: 10.1136/gut.50.6.877. View

Vilgrain V, Uzan F, Brancatelli G, Federle M, Zappa M, Menu Y . Prevalence of hepatic hemangioma in patients with focal nodular hyperplasia: MR imaging analysis. Radiology. 2003; 229(1):75-9. DOI: 10.1148/radiol.2291021284. View

Cobey F, Salem R . A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg. 2004; 187(2):181-91. DOI: 10.1016/j.amjsurg.2003.11.016. View

10.

Byrnes V, Cardenas A, Afdhal N, Hanto D . Symptomatic focal nodular hyperplasia during pregnancy: a case report. Ann Hepatol. 2004; 3(1):35-7. View

11.

Kim J, Nikiforov Y, Moulton J, Lowy A . Multiple focal nodular hyperplasia of the liver in a 21-year-old woman. J Gastrointest Surg. 2004; 8(5):591-5. DOI: 10.1016/j.gassur.2003.11.012. View

12.

Baum J, Bookstein J, Holtz F, KLEIN E . Possible association between benign hepatomas and oral contraceptives. Lancet. 1973; 2(7835):926-9. DOI: 10.1016/s0140-6736(73)92594-4. View

13.

Moesner J, Baunsgaard P, Starklint H, Thommesen N . Focal nodular hyperplasia of the liver. Possible influence of female reproductive steroids on the histological picture. Acta Pathol Microbiol Scand A. 1977; 85A(2):113-21. View

14.

Nime F, PICKREN J, Vana J, ARONOFF B, Baker H, Murphy G . The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer. 1979; 44(4):1481-9. DOI: 10.1002/1097-0142(197910)44:4<1481::aid-cncr2820440443>3.0.co;2-1. View

15.

Charny C, Jarnagin W, Schwartz L, Frommeyer H, DeMatteo R, Fong Y . Management of 155 patients with benign liver tumours. Br J Surg. 2001; 88(6):808-13. DOI: 10.1046/j.0007-1323.2001.01771.x. View

16.

Wanless I, Mawdsley C, Adams R . On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology. 1985; 5(6):1194-200. DOI: 10.1002/hep.1840050622. View

17.

Karhunen P . Benign hepatic tumours and tumour like conditions in men. J Clin Pathol. 1986; 39(2):183-8. PMC: 499674. DOI: 10.1136/jcp.39.2.183. View

18.

Porter L, Elm M, Van Thiel D, Eagon P . Hepatic estrogen receptor in human liver disease. Gastroenterology. 1987; 92(3):735-45. DOI: 10.1016/0016-5085(87)90026-6. View

19.

Wanless I . Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990; 11(5):787-97. DOI: 10.1002/hep.1840110512. View

20.

Pain J, Gimson A, Williams R, Howard E . Focal nodular hyperplasia of the liver: results of treatment and options in management. Gut. 1991; 32(5):524-7. PMC: 1378930. DOI: 10.1136/gut.32.5.524. View